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Abstract
Background & Aims: Four gamma-gultamyltransferases (GGT) fractions (b-,
m-, s-, and f-GGT) have been identified in human plasma and their concen-
trations and ratios vary in different pathological conditions. To assess the
behaviour of fractional GGT in cirrhotic patients evaluated for liver trans-
plantation. Methods: This was a single-centre, cross-sectional study; GGT
fractions were determined by gel-filtration chromatography. Results: 264
cirrhotic patients (215 males; median age 54.5 years) were included and
compared against a group of 200 healthy individuals (100 males; median age
41.5). Median (25th–75th percentile) total and fractional GGT were higher
in cirrhotics, with s-GGT showing the greatest increase [36.6 U/L (21.0–
81.4) vs. 5.6 U/L (3.2–10.2), P < 0.0001], while the median b-GGT/s-GGT
ratio was lower in cirrhotics than in healthy controls [0.06 (0.04–0.10)] vs.
0.28 (0.20–0.40), P < 0.0001]. The ratio showed higher diagnostic accuracy
(ROC-AUC, 95% CI: 0.951, 0.927–0.969) then either s-GGT (0.924, 0.897–
0.947; P < 0.05) or total GGT (0.900, 0.869–0.925; P < 0.001). The diagnos-
tic accuracy of the ratio was maintained (0.940, 0.907–0.963) in cirrhotic
patients (n = 113) with total GGT values within the reference range. The s-
GGT fraction consisted of two components, with one (s2-GGT) showing a
significant positive correlation with serum aspartate aminotransferases, ala-
nine aminotransferase, lactate dehydrogenases (LDH), alkaline phosphatases
and bilirubin, and negative with albumin. The b-GGT fraction showed a
positive correlation with albumin, fibrinogen, and platelet counts, and
negative with international normalized ratio, bilirubin and LDH. Conclu-
sions: The ratio performs as a sensitive biomarker of the liver parenchymal
rearrangement, irrespective of aetiology of cirrhosis and presence of hepato-
cellular carcinoma, even in patients with total GGT values within the
reference range.
In the liver, the enzyme gamma-glutamyltransferase
(GGT) is expressed in the biliary canaliculi and on the
luminal side of the bile ducts (1, 2). Liver diseases are
the main causes of plasma GGT increase (1), making
GGT a biomarker of hepato-biliary disease and alco-
hol abuse (3, 4). During the last decade, a series of
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large-scale, prospective studies have shown that plasma
GGT values above the median, albeit within the refer-
ence range, are independent predictors of the risk of car-
diovascular mortality (5), stroke (6, 7) and metabolic
syndrome (8–10), including its individual components,
such as hyperglycaemia, hypertension and dyslipida-
emia, and irrespective of alcohol consumption and liver
diseases (11–14).
By use of a high-sensitivity molecular size-exclusion
procedure we previously reported that four GGT frac-
tions (i.e. b-GGT, m-GGT, s-GGT, and f-GGT) with
molecular weights ranging from 2000 to 70 kDa are
present in the human plasma (15, 16), and that different
patterns of fractional GGT are associated with distinct
pathological conditions (17, 18). The evidence collected
to date suggests that the higher concentrations of the
high-molecular-weight b-GGT are associated with car-
diovascular and metabolic disease (17, 19, 20), while the
s-GGT is a biomarker of liver injury and architectural
rearrangement (17, 18). The s-GGT is a supramolecular
complex with a molecular weight similar to high density
lipoprotein (HDL) cholesterol, and its increase has been
reported in alcohol abuse (18) and chronic hepatitis
(17). On the opposite, the b-GGT has a molecular size
similar to very low density lipoprotein (VLDL), and
increased levels have been reported in non-alcoholic
fatty liver disease (NAFLD) concurrent with heightened
s-GGT expression (17). In turn, the f-GGT fraction,
which corresponds to the hydrophilic form of the
enzyme, is the most frequent one expressed in healthy
individuals (16). Studies in humans, rodents and large
laboratory animals have shown that the four-GGT-frac-
tion pattern is shared by all adult mammalians, and that
during embryonic development the b-GGT is the first to
appear and the f-GGT is the last, suggesting that a fully
functional liver architecture is required to deploy and
maintain this pattern (21).
Scanty information is still available on the fractional
GGT pattern expressed in cirrhosis. To that regard, we
designed a cross-sectional study to explore the expres-
sion of total and fractional GGT in cirrhotic patients
referred for liver transplantation (LT), and to assess
their correlation with routine biomarkers of liver func-
tion.
Materials and methods
Study design and patient selection
This was a single-centre, cross-sectional study on
patients with cirrhosis referred for evaluation of eligibil-
ity to LT and compared against a historical cohort of
healthy individuals enrolled in previous research on
total and fractional GGT (16). This study was initiated
in February 2008 at the Hepatobiliary Surgery and Liver
Transplantation Unit of the University of Pisa Medical
School Hospital in collaboration with the Department
of Translational Research and Novel Technologies, the
Department of Cardiovascular Medicine, Gabriele Mon-
asterio Foundation, National Research Council, and the
Sant’Anna Institute of High Education, Pisa, Italy.
The inclusion criteria called for adult (≥18 years),
consenting patients affected with cirrhosis of viral, met-
abolic, toxic and autoimmune aetiology, and undergo-
ing evaluation for deceased donor LT. Patients were
excluded if unable to provide an informed consent; on
active alcohol use ≤6 months prior to evaluation;
affected with hepatocellular carcinoma (HCC) with
macrovascular infiltration and/or extra-hepatic disease;
affected with non-HCC malignancies; on active steroid
and/or anti-hepatitis C virus (HCV) treatment; with
renal failure with a creatinine clearance (CrCl) ≤30 ml/
min according to the Cockroft Gault’s formula; affected
with systemic infection of extrahepatic origin; affected
with fulminant liver failure; and if on dialysis or
mechanical ventilation.
Blood samples were obtained after an overnight fast-
ing on the first day of the outpatient and/or inpatient
pretransplant workup and included liver function tests
(LFT), serology, virology and the autoimmune panel. A
diagnosis of cirrhosis was based as the composite of
medical history, physical examination, liver function
tests, serologic studies, radiology and histology, as clini-
cally appropriate. HCC was diagnosed according to the
American Association for the Study of Liver Disease
2005 guidelines, eventually updated in 2010 (22). The
severity of liver disease was graded according to the
model for end-stage liver disease (MELD) scoring sys-
tem, which is based on 3 variables (serum bilirubin,
serum creatinine and international normalized ratio
(INR) and is able to estimate 3-month mortality in
patients with chronic end-stage liver disease more accu-
rately than the Child-Turcotte-Pugh score (23, 24).
MELD is the score of choice for deceased donor alloca-
tion since 2002 in the United States and 2006 in the
euro-transplant countries (25, 26).
This study was approved by the internal review board
and carried out in compliance with the principles set
forth in the Declaration of Helsinki.
Laboratory analyses and score calculations
Standard assay of all blood tests were simultaneously
performed according to the clinical laboratory proce-
dures by automated analysers at the Clinical Laborato-
ries of the Pisa University Hospital, and included: red
blood count; white blood count; platelet count; INR;
fibrinogen (FBG); aspartate aminotransferases (AST);
alanine aminotransferases (ALT); alkaline phosphatases
(ALP); bilirubin (BIL); serum electrolytes; total protein;
serum albumin (ALB); total triglycerides (TRG); total
cholesterol (CHOL); low density lipoprotein (LDL);
HDL; VLDL; viral serology for hepatitis B (HBV), HCV,
hepatitis delta, and human immunodeficiency virus as
appropriate. The CrCl was calculated with the
Cockcroft-Gault formula [CrCl ml/min = [(140  age)
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9 kg/(creatinine mg/dl 9 72)] 9 0.85 for women)]
(27). The LDL cholesterol was calculated using the
Friedewald formula [LDL-C = total cholesterol  HDL
cholesterol  (triglycerides/5)]. The MELD score was
derived according to the formula: MELD = 9.57 9 ln
(creatinine) (mg/dl) + 3.78 9 ln(total bilirubin) (mg/dl)
+ 11.20 9 ln(INR) + 6.43 (23).
Total and fractional GGT determination
Analysis of total and fractional GGT was performed, as
previously described (15, 16) (pat. pend. WO2009/
001290-A3, The University of Pisa), on plasma-EDTA
(ethylenediamine-tetra-acetic acid) samples using an
FPLC (fast protein liquid chromatography) system
(AKTA purifier, GE Healthcare Europe, Milan, Italy)
equipped with a gel filtration column (Superose 6 HR
10/300 GL, GE Healthcare Europe) and fluorescence
detector (Jasco FP-2020, Jasco Europe, Lecco, Italy).
Separation of fractional GGT was obtained by gel fil-
tration chromatography and the enzymatic activity
was quantified by post-column injection of the fluo-
rescent substrate for GGT, gamma-glutamyl-7-amido-
4-methylcoumarin (gGluAMC). Enzymatic reaction,
in the presence of gGluAMC 0.030 mmol/L and gly-
cylglycine 4.5 mmol/L, proceeded for 4.5 min in a
reaction coil (PFA, 2.6 ml) kept at the 37°C in a
water bath. The fluorescence detector operating at
excitation/emission wavelengths of 380/440 nm
detected the AMC signal; the intensity of the fluores-
cence signal was expressed in arbitrary fluorescence
units (f.u.), and the area under curve is proportional
to GGT activity.
The total GGT and fractional GGT areas were cal-
culated by a MatLab program (Version 7 MathWorks,
Inc., Natick, MA, USA) to resolve overlapping peaks;
the curve fitting was conducted with a nonlinear
least-squares minimization algorithm using four expo-
nentially modified Gaussian (EMG) curves. The reac-
tion was calibrated analysing plasma samples with
known total GGT activity (standards). The slope of
the calibration curve was used to convert total and
fractional GGT area to U/L (16).
A 4.5 mmol/L stock solution of gGluAMC was
prepared in ethanol 30% w/w containing 0.005 N
NaOH and stored at –20°C. This solution was daily
diluted 25-fold into 0.25 M Tris-HCl buffer pH 8.5
(25°C).
Statistical analysis
Data are presented as means ± standard deviation,
medians, percentiles, frequencies and ranges as appro-
priate. According to the and level of distribution of the
variables, the statistical analysis was carried out with the
Student’s t-test or 1-way ANOVA followed by the Bonfer-
roni’s multiple comparison test for continuously dis-
tributed values. Total GGT, b-, m- and s-GGT fractions,
as well as b-GGT/s-GGT ratio, triglycerides and body
mass index values were ln-transformed to reduce the
distribution skewness. f-GGT fraction data were not ln-
transformed because they were normally distributed
(16). Bivariate linear correlations between biological
variables and fractional GGT activity were evaluated
with the Spearman’s correlation coefficient. A Receiver
Operating Characteristics curve analysis (ROC) was per-
formed to assess the diagnostic accuracy of total and
fractional GGT values and of the b-GGT/s-GGT ratio.
The ROC analysis and the comparison between ROC
curves were performed with MedCalc 11.5 analysis soft-
ware on the basis of the De Long method described else-
where (28). Positive and negative predictive value have
been calculated as if the ratio of healthy and diseases
subjects considered in this study reflects the prevalence
of disease.
Results
Patients
Between February 2008 and April 2011, we enrolled a
total of 264 patients (215 males (81.4%)) of a median
age (25th–75th percentile) of 54.5 (50–60). Based on
previous research on total and fractional GGT (17),
patients were divided according to aetiology of liver dis-
ease and/or presence of HCC: 17 (6.4%) were affected
with metabolic cirrhosis (MET); 22 (8.3%) with alco-
holic cirrhosis (ALC); 96 (36.4%) with viral cirrhosis
because of HCV and/or HBV infection (VIR); and 129
(48.9%) with HCC in the setting of cirrhosis of viral
origin (HCC). Two hundred healthy individuals
included in previous research on total and fractional
GGT reference values were used as the historical con-
trol cohort [100 males (50%); median age (25th–75th
percentile) 41.5 (35.0–50.0) years] (16). Table 1 illus-
trates the demographic, clinical and biochemical char-
acteristic of the study population of cirrhotics and of
the 200 healthy controls. The two populations were
different for gender and age, with cirrhotics being
predominantly males and older than healthy individu-
als (Table 1).
Laboratory tests
The study group of cirrhotics showed higher AST, ALT,
ALP, total bilirubin, lactate dehydrogenases (LDH), INR
and triglycerides, while serum albumin, total cholesterol
and platelet counts were lower vs. healthy controls
(Table 1). Total and fractional GGT were higher in cir-
rhotics (Table 1). The s-GGT showed a higher increase,
and was the most abundant fraction in cirrhosis
(Table 1). The b-GGT/s-GGT ratio was significantly
lower in cirrhosis vs. the healthy controls (Table 1). In
both groups the total GGT level, all of its fractions and
the b-GGT/s-GGT ratio showed a right-skewed distribu-
tion (P < 0.0001). Of the 264 cirrhotic patients, 113
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[42.8%; 104 males (92.0%)] showed median (25th–75th
percentile) total GGT values within the reference range
(16), i.e. 35.6 U/L (25.8–45.7) (Supplementary
Table S1) (males: total GGT <60.5 U/L, females:
<30.9 U/L).
ROC analysis
When comparing healthy subjects with cirrhotics, the s-
GGT showed higher specificity and sensitivity for cir-
rhosis [area under the curve (AUC), 95% CI: 0.924,
Table 1. Comparison of the characteristics of the healthy subjects (#200) and study patients (#264)
Healthy Subjects (n = 200) Cirrhosis (n = 264) P
Males, n (%) 100 (50%) 215 (81%) <0.0001
Age, years 41.5 35.0–50.0 54.5 50.0–60.0 <0.0001
MELD 11.9 9.1–14.9
BMI*, kg/m2 24.3 22.2–26.6 24.8 23.1–26.8 n.s.
SBP, mmHg 120.0 110.0–120.0 120.0 110.0–130.0 n.s.
DBP, mmHg 80.0 70.0–80.0 70.0 70.0–80.0 0.0003
Heart rate, bpm 70.0 64.0–75.5 68.0 60.0–75.0 n.s.
Glucose, mg/dl 93.0 86.0–100.0 101.0 93.0–116.0 <0.0001
Creatinine, mg/dl 0.9 0.8–1.0 0.8 0.7–0.9 n.s.
CrCl, ml/min 104.5 91.5–119.2 107.5 89.5–130.7 n.s.
CHOL, mg/dl 187.5 160.8–209.3 139.5 118.8–166.0 <0.0001
HDL cholesterol, mg/dl 51.0 43.0–62.0 49.0 37.0–61.0 0.0306
LDL cholesterol, mg/dl 116.5 97.0–135.0 75.0 56.8–96.0 <0.0001
TRG*, mg/dl 73.0 50.0–106.5 83.5 69.5–112.0 0.0008
AST, U/L 17.0 14.0–21.0 70.0 43.8–106.3 <0.0001
ALT, U/L 17.0 12.0–24.5 50.0 33.0–81.0 <0.0001
BIL, mg/dl 0.7 0.6–0.9 1.6 0.9–2.9 <0.0001
ALP, U/L 129.5 94.8–182.0
LDH, U/L 198.5 166.0–244.8
ALB, g/dl 3.9 3.6–4.3
Haemoglobin, g/dl 14.7 13.6–15.8 12.9 11.9–14.5 <0.0001
WBC, 9109 L 6.2 5.4–7.6 4.3 3.6–5.7 <0.0001
PLT, 109/L 249.0 212.0–283.0 75.5 58.0–111.5 <0.0001
INR 1.4 1.2–1.5
FBG, mg/dl 217.0 183.8–270.3
Total GGT*, U/L 18.8 13.8–28.7 61.1 40.3–113.5 <0.0001
b-GGT*, U/L 1.6 0.9–3.0 2.6 1.4–5.3 <0.0001
m-GGT*, U/L 0.6 0.4–1.1 3.1 1.5–6.7 <0.0001
s-GGT*, U/L 5.6 3.2–10.2 36.6 21.0–81.4 <0.0001
f-GGT, U/L 10.4 8.6–13.4 16.2 13.6–20.4 <0.0001
b/s ratio* 0.28 0.20–0.40 0.06 0.04–0.10 <0.0001
Data are reported as median, 25th–75th percentile. CrCl was estimated with the Cockcroft–Gault formula; LDL cholesterol was estimated with the
Friedewald formula. ALP, LDH, albumin, INR and fibrinogen were not assessed in healthy subjects (blood donors).
*Student’s t-test performed on ln-transformed data.
ALB, albumin; ALP, Alkaline phosphatase; ALT, alanine aminotransferase; AST, aspartate aminotransferase; BIL, total bilirubin; BMI, body mass index;
CHOL, total cholesterol; CrCl, creatinine clearance; DBP, diastolic blood pressure; FBG, fibrinogen; INR, international normalized ratio; GGT, gamma-
glutamyltransferase; LDH, lactate dehydrogenase; MELD, model for end-stage liver disease (MELD) scoring system; SBP, systolic blood pressure; TRG,
triglycerides; WBC, white blood cells. n.s., not significant.
Table 2. Diagnostic power of total, fractional GGT and of the b-GGT/s-GGT ratio in patients with cirrhosis and healthy subjects (HS)
HS (n = 200) vs. Cirrhosis
(n = 264) P-value vs. b/s ratio
Tot-GGT within ref. range:
HS (n = 200) vs. Cirrhosis
(n = 113) P-value vs. b/s ratio
Total GGT 0.900 0.869–0.925 0.010 0.789 0.740–0.833 <0.0001
b-GGT 0.616 0.570–0.661 <0.0001 0.628 0.672–0.773 <0.0001
m-GGT 0.868 0.833–0.897 <0.0001 0.724 0.671–0.773 <0.0001
s-GGT 0.924 0.897–0.947 0.0460 0.843 0.789–0.881 <0.0001
f-GGT 0.805 0.766–0.840 0.0001 0.672 0.617–0.724 <0.0001
b/s ratio 0.951 0.927–0.969 0.940 0.907–0.963
Data are presented as ROC-AUC (95% CI). ROC-AUC, area under the receiver operating characteristic curve.
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0.897–0.947], but the b-GGT/s-GGT ratio showed a sig-
nificantly higher AUC (0.951, 0.927–0.969) vs. either the
s-GGT (P = 0.046) or total GGT (0.900, 0.869–0.925;
P = 0.010) (Table 2; Figure 1A). The best cut-off value
for b-GGT/s-GGT ratio was 0.13 [sensitivity (95% CI):
87.1% (82.5–90.0); specificity: 91.0% (86.1–94.6); posi-
(A) (B)
Fig. 1. ROC analysis of total and fractional GGT in patients affected with cirrhosis vs. healthy subjects: (A) whole population; (B) total GGT
within reference range. b-GGT/s-GGT, black solid line; b-GGT, dotted line; s-GGT, dashed line; total GGT, gray solid line.
(A) (B) (C) (D)
(E) (F) (G) (H)
Fig. 2. Calculated elution profile (A–D) of fractional GGT activity corresponding to the 25th (dotted line), 50th (solid line) and 75th (dashed line)
percentile and a representative chromatogram (E–H) of patients affected by: viral cirrhosis (A, E), metabolic cirrhosis (B, F), alcoholic cirrhosis (C,
G) or cirrhosis and hepatocellular carcinoma (D, H). Fractional GGT analysis was performed on plasma-EDTA samples by high performance gel-
filtration chromatography; GGT activity was specifically detected by an online post-column reaction with a fluorescent substrate.
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tive likelihood ratio: 9.68; negative likelihood ratio:
0.14; positive predictive value: 92.7; negative predictive
value: 84.3].
In patients with total GGT within the reference range
(n = 113) the diagnostic accuracy of the b-GGT/s-GGT
ratio was maintained (AUC, 95% CI: 0.940, 0.907–
0.963), while that of all other fractions dropped to lower
values (m-, s-GGT amd f-GGT) or showed a moderate
(b-GGT) (Table 2, Figure 1B). In this case the best cut-
off value for b-GGT/s-GGT ratio was 0.12 [sensitivity
(95% CI): 83.2% (75.0–89.6); specificity: 94.0% (89.8–
96.9); positive likelihood ratio: 13.8; negative likelihood
ratio: 0.18; positive predictive value: 88.7; negative pre-
dictive value: 90.8].
Fractional GGT activity
To better assess the behaviour of the GGT fractions in
cirrhosis and HCC, the four subcohorts of patients
(HCC, VIR, MET, ALC) were compared. Figure 2
shows the calculated elution profile of each of the three
subgroups, corresponding to the 25th, 50th and 75th
percentile of the distribution, and the actual chromato-
graphic profile of a representative individual patient of
each group. In all subcohorts, the s-GGT elution profile
was broader than in healthy individuals and consisted of
two Gaussian components that were eventually mathe-
matically defined and named s1-GGT and s2-GGT. The
s-GGT double profile was not observed in healthy con-
trols. The differences observed across groups regarding
total and fractional GGT (Table 3) were that in VIR
patients both the b-GGT and the b-GGT/s-GGT ratio
were lower vs. MET, while HCC patients showed higher
values of total, b-, m- and s1-GGT compared with the
VIR group, but not to the MET or ALC groups. In all of
the four groups (Table 3), the b-GGT/s-GGT ratio was
lower than in controls (Table 1) and was not correlated
with total GGT, aetiology of cirrhosis or the presence of
HCC.
The results of the correlation analysis between frac-
tional GGT and laboratory tests showed that TRG and
CHOL were positively correlated with all of the GGT
fractions, as well as the b-GGT/s-GGT ratio. However,
some specific patterns of associations emerged between
fractional GGT and LFTs (Table 4). Namely, the b-GGT
showed a positive correlation with ALB and FBG, and a
negative correlation with INR, but no or negative corre-
lation with AST, and ALT, ALP, BIL and LDH. As a
result, the b-GGT showed a negative correlation with
the MELD score. The s2-GGT fraction showed a statisti-
cally significant positive correlation with AST, ALT,
LDH, ALP and BIL, but a negative association with
ALB, and no association with INR and FBG. The two
s-GGT fractions – s1-GGT and s2-GGT showed indepen-
dent behaviour for some variables (e.g. ALB, INR and
FBG were significantly correlated with one only), and
sometimes opposite behaviour for others (BIL and LDH
showed opposite correlations with s1 and s2-GGT). The Ta
b
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m-GGT and f-GGT also displayed different association
with the LFTs, with the f-GGT mostly corresponding to
s2-GGT. The b-GGT/s-GGT ratio showed negative cor-
relations mostly with indexes of hepatocellular damage
(i.e. AST, ALT), or positive with marker of hepatocyte
function (i.e. albumin, FBG), accordingly to an increase
of s-GGT or b-GGT fraction respectively. Representative
scatter plot for correlations are provided in Supplemen-
tary Figure S1.
Discussion
The current cross-sectional study shows that the b-
GGT/s-GGT ratio has a high sensitivity and specificity
for cirrhosis, irrespective of the levels of total and frac-
tional GGT. The area under the ROC curve as well as
the best cut-off were comparable in the whole cohort of
cirrhotics vs. the subset of patients with total GGT
within the reference range, and the b-GGT/s-GGT ratio
was lower than in controls across all aetiologies or the
presence of HCC. These data suggest that the b-GGT/s-
GGT ratio behaves as a specific biomarker for the liver
structural rearrangement, and that the mechanisms
responsible for a decreased b-GGT/s-GGT ratio are dif-
ferent than those leading to the increase of total GGT
values observed in liver disease. Consistently with this,
in a previous study we already reported a decreased b-
GGT/s-GGT ratio in chronic HCV-related hepatitis vs.
NAFLD (17). Furthermore, the b-GGT/s-GGT ratio
observed in the cirrhotic patients enrolled in this study
(0.06, 0.04–0.1) was lower than in previous chronic
HCV-related hepatitis patients (0.10, 0.07–015) (17),
suggesting that the b-GGT/s-GGT ratio may act as an
indicator of progression of liver fibrosis.
With regard to the individual GGT fractions, our
study underlines that the b-GGT is correlated with liver
function, as suggested by the positive association with
serum albumin, fibrinogen, platelet counts, and the
negative association with INR. On the opposite, the
s-GGT – and its component s2-GGT in particular –
behaves as a marker of cell injury and cholestasis, show-
ing a positive association with AST, ALT, LDH, ALP and
bilirubin, and a negative association with serum albumin.
On the other hand the correlations found are quite low,
suggesting that we have not identified yet the main role
of GGT in liver metabolism. Elucidation of the mecha-
nisms leading to production and release of the GGT frac-
tions is pivotal to better understanding of the link
between GGT, its fractions and liver physiopathology,
thus explaining also the correlations found in this study.
Despite their heterogeneity – with molecular weights
ranging from 2000 (b-GGT) to 70 kDa (f-GGT) – all of
the GGT fractions share an identical GGT peptide
encoded by the GGT1 gene. However, the GGT fractions
differ in that this peptide is linked to different carriers
whose nature has not yet been entirely described (b, m-,
s-GGTs), or it originates from hydrolysis of an other-
wise strongly hydrophobic GGT peptide by a yet
unknown protease (f-GGT). Describing in detail these
mechanisms will likely improve our understanding of
liver function and of pathogenesis of liver disease. The
evidence collected to date confirms that the biogenesis
of the GGT fractions replicates liver function and struc-
ture. Studies in rodents have shown that the b-GGT
represents the fetal form of the circulating GGT, while
s-GGT appears at birth, and f-GGT becomes the main
fraction at weaning (21). In healthy controls, the b-GGT
showed a strong association with the traditional risk fac-
tors for cardiovascular disease and metabolic syndrome,
such as serum lipids and arterial blood pressure (19).
In conclusion, the b-GGT/s-GGT ratio showed to be
a highly sensitive biomarker of liver structural rear-
rangement, even in patients with total GGT values
within the reference range. The diagnosis of cirrhosis in
patients evaluated for liver transplantation does not
require any further biochemical analysis by a clinical
point of view, anyway this study together with the previ-
ous ones (17, 18) represent the base for planning future
Table 4. Linear correlation analysis between biological variables and fractional GGT activity
Variables TOT GGT b-GGT m-GGT s1-GGT s2-GGT f-GGT b-GGT/s-GGT
MELD score 0.216† 0.283‡ n.s. 0.300‡ 0.166§ n.s. n.s.
CHOL, mg/dl 0.456‡ 0.508‡ 0.480‡ 0.473‡ 0.166§ 0.277‡ 0.214†
TRG, mg/dl 0.337‡ 0.351‡ 0.420‡ 0.301‡ 0.214† 0.289‡ 0.142*
PLT, 109/L n.s. 0.180§ n.s. n.s. n.s. n.s. 0.190§
BIL, mg/dl 0.181‡ 0.268‡ n.s. 0.264‡ 0.175§ n.s. n.s.
ALP, U/L 0.232† n.s. 0.315‡ 0.155* 0.415§ 0.359‡ n.s.
AST, U/L 0.157* n.s. 0.199§ n.s. 0.413‡ 0.283‡ 0.344‡
ALT, U/L 0.276‡ n.s. 0.255‡ 0.249‡ 0.409‡ 0.320‡ 0.306‡
LDH, U/L n.s. 0.181§ n.s. 0.148* 0.200‡ 0.183§ n.s.
ALB, g/dl n.s. 0.260‡ n.s. n.s. 0.240† n.s. 0.300‡
INR 0.269‡ 0.361‡ 0.172§ 0.327‡ n.s. n.s. 0.161§
FBG, mg/dl 0.264‡ 0.438‡ 0.228† 0.286‡ n.s. 0.163§ 0.355‡
Data are reported as Spearman correlation coefficients.
Statistical significance levels: *P < 0.05; §P < 0.01; †P < 0.001; ‡P < 0.0001.
ALB, albumin; ALP, alkaline phosphatase; ALT, alanine aminotransferase; AST, aspartate aminotransferase; CHOL, cholesterol; FBG, fibrinogen;
INR, international normalized ratio; LDH, lactate dehydrogenase; TRG, triglycerides. n.s., not significant.
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studies aimed to verify if the b-GGT/s-GGT ratio may
act as an indicator of progression of liver fibrosis and to
compare its specificity and sensitivity with established
test, such as Fibroscan (29). Recently, several algo-
rithms, based on the dosage of serum biomarkers, have
been validated as surrogate markers of liver fibrosis;
some of these include also total GGT values, i.e.: Fibro-
Test-ActiTest (30), Hepatoscore (31), the model devel-
oped by Forns and colleagues (32). Thus, it will be of
interest to verify if GGT fractions and the b-GGT/s-
GGT ratio may increase the predicting power of these
tests, bettering the stratification of patients.
Further research on the nature and biological role of
the GGT fractions is strongly favoured and will help
improve the use of this biomarker for diagnosis and
prognosis of liver disease and monitoring of progression
of fibrosis.
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Supporting information
Additional Supporting Information may be found in the
online version of this article:
Table S1. Total and fractional GGT activity (U/L) in
patients affected by cirrhosis and with total GGT values
within the reference range (n = 113; 104 males).
Figure S1. Representative scatter plots for correla-
tions between fractional GGT, the b-GGT/s-GGT ratio
and a representative marker of hepatocellular damage
(ALT), liver synthetic capability (albumin) and liver
metabolism (total cholesterol).
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